Verdeso is a drug owned by Almirall Llc. It is protected by 5 US drug patents filed from 2013 to 2016. Out of these, 3 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 13, 2027. Details of Verdeso's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8460641 | Microemulsion process and composition |
Aug, 2027
(2 years from now) | Active |
| US9492384 | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(8 months from now) | Active |
| US8962000 | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(8 months from now) | Active |
| US6730288 | Mousse composition |
Sep, 2019
(5 years ago) |
Expired
|
| US7029659 | Mousse composition |
Sep, 2019
(5 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Verdeso's patents.
Latest Legal Activities on Verdeso's Patents
Given below is the list of recent legal activities going on the following patents of Verdeso.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Apr, 2024 | US9492384 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Apr, 2020 | US9492384 |
| Patent Issue Date Used in PTA Calculation Critical | 15 Nov, 2016 | US9492384 |
| Recordation of Patent Grant Mailed Critical | 15 Nov, 2016 | US9492384 |
| Email Notification Critical | 27 Oct, 2016 | US9492384 |
| Issue Notification Mailed Critical | 26 Oct, 2016 | US9492384 |
| Dispatch to FDC | 17 Oct, 2016 | US9492384 |
| Application Is Considered Ready for Issue Critical | 14 Oct, 2016 | US9492384 |
| Issue Fee Payment Received Critical | 13 Oct, 2016 | US9492384 |
| Issue Fee Payment Verified Critical | 13 Oct, 2016 | US9492384 |
Several oppositions have been filed on Verdeso's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Verdeso's generic, the next section provides detailed information on ongoing and past EP oppositions related to Verdeso patents.
Verdeso's Oppositions Filed in EPO
Verdeso has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 14, 2014, by Generics [Uk] Limited. This opposition was filed on patent number EP05775966A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP05775966A | May, 2014 | Henkel AG & Co. KGaA | Patent maintained as amended |
| EP05775966A | May, 2014 | Generics [UK] Limited | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Verdeso is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Verdeso's family patents as well as insights into ongoing legal events on those patents.
Verdeso's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Verdeso's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 13, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Verdeso Generic API suppliers:
Desonide is the generic name for the brand Verdeso. 12 different companies have already filed for the generic of Verdeso, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Verdeso's generic
Alternative Brands for Verdeso
Verdeso which is used for treating atopic dermatitis., has several other brand drugs in the same treatment category and using the same active ingredient (Desonide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Almirall |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Desonide. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||||
|---|---|---|---|---|---|---|
| Astrazeneca |
| |||||
| Astrazeneca Ab |
| |||||
| Calliditas |
| |||||
| Cheplapharm |
| |||||
| Leo Pharma As |
| |||||
| Padagis Us |
| |||||
| Salix |
| |||||
| Sun Pharm Inds Inc |
| |||||
| Takeda Pharms Usa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Desonide, Verdeso's active ingredient. Check the complete list of approved generic manufacturers for Verdeso
About Verdeso
Verdeso is a drug owned by Almirall Llc. It is used for treating atopic dermatitis. Verdeso uses Desonide as an active ingredient. Verdeso was launched by Almirall in 2006.
Approval Date:
Verdeso was approved by FDA for market use on 19 September, 2006.
Active Ingredient:
Verdeso uses Desonide as the active ingredient. Check out other Drugs and Companies using Desonide ingredient
Treatment:
Verdeso is used for treating atopic dermatitis.
Dosage:
Verdeso is available in aerosol, foam form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05% | AEROSOL, FOAM | Discontinued | TOPICAL |